Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 5,204 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thoracic Neoplasm Clear all
Terminated Phase 1 Interventional

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

NCT05571839
View directory record Official record
Conditions
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
Interventions
PF-08046049
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
27
States / cities
Los Angeles, California • Pasadena, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Recruiting Phase 1 Interventional

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

NCT03760575
View directory record Official record
Conditions
Mesotheliomas Pleural
Interventions
Pembrolizumab, Indocyanine Green (ICG) Image-Guided Surgery, Cisplatin, Pemetrexed
Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 30, 2026, 2:38 PM EDT
Terminated Phase 2 Interventional

Dietary Flaxseed in NSCLC

NCT02475330
View directory record Official record
Conditions
Lung Cancer
Interventions
Flaxseed
Dietary Supplement
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 30, 2026, 2:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

NCT06914128
View directory record Official record
Conditions
MTAP-deleted Solid Tumors
Interventions
BAY 3713372
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

NCT02027428
View directory record Official record
Conditions
Squamous Cell Carcinoma, Non-Small-Cell Lung
Interventions
Abraxane (Induction), Carboplatin (Induction), Abraxane (Maintenance), Best Supportive Care (Maintenance)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
91
States / cities
Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Emergency Department Lung Cancer URMFG Pilot

NCT04979169
View directory record Official record
Conditions
Lung Cancer
Interventions
Text Messaging
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
50 Years to 80 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 30, 2026, 2:38 PM EDT
Active, not recruiting Phase 1 Interventional

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

NCT06333951
View directory record Official record
Conditions
Thoracic Tumors, Non-small Cell Lung Cancer
Interventions
Anvumetostat, Carboplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Sotorasib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Bakersfield, California • Duarte, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00550537
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, gene expression analysis, protein expression analysis, proteomic profiling, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
7
States / cities
Gainesville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

NCT00111839
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Carcinoma
Interventions
Pemetrexed, Matuzumab
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
42
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 30, 2026, 2:38 PM EDT
Active, not recruiting Phase 1 Interventional

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

NCT03220477
View directory record Official record
Conditions
Lung Cancer
Interventions
Pembrolizumab, Guadecitabine, Mocetinostat
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Not applicable Interventional Results available

Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer

NCT02111681
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Calypso Beacon Implantation
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
4
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 30, 2026, 2:38 PM EDT
Recruiting Phase 1 Interventional

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

NCT05136846
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Durvalumab, Paclitaxel, Papaverine, Radiation Therapy, Pemetrexed, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging of the Brain with and without Contrast, Biospecimen Collection
Drug · Biological · Radiation + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Duarte, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Recruiting No phase listed Observational

An External Control Arm Study in Non-Small Cell Lung Cancer

NCT07174388
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
N-Power Medicine
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Monterey, California • Dover, Delaware • Milford, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Completed No phase listed Observational

A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.

NCT05230186
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Tumor Biopsy
Procedure
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • New Orleans, Louisiana • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Active, not recruiting Phase 3 Interventional

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT03391869
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Ipilimumab, Local Consolidation Therapy, Nivolumab, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery
Biological · Procedure · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Not listed Phase 2Phase 3 Interventional

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

NCT00030641
View directory record Official record
Conditions
Lung Cancer
Interventions
oblimersen sodium, docetaxel
Biological · Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
35
States / cities
Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 30, 2026, 2:38 PM EDT
Terminated Phase 1 Interventional

Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer

NCT00958022
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
LBH589 and carboplatin with etoposide
Drug
Lead sponsor
Ahmad Tarhini
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 30, 2026, 2:38 PM EDT
Terminated Not applicable Interventional

Study Comparing EBUS & EUS to Mediastinoscopy in Staging and Detection of Lung Cancer

NCT00970645
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Mediastinoscopy/thoracoscopy, EBUS/EUS
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Jacksonville, Florida • Rochester, Minnesota • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 18, 2011 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer

NCT00006877
View directory record Official record
Conditions
Lung Cancer
Interventions
temozolomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

NCT00003022
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Neuroblastoma, Retinoblastoma, Sarcoma
Interventions
iodine I 131 monoclonal antibody 3F8
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Not applicable Interventional

Lung Cancer Screening: A Multilevel Intervention

NCT03862001
View directory record Official record
Conditions
Lung Cancer
Interventions
LungCARE
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 30, 2026, 2:38 PM EDT
Active, not recruiting Phase 1 Interventional

TH1902 in Patients With Advanced Solid Tumors

NCT04706962
View directory record Official record
Conditions
Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
Interventions
TH1902
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Detroit, Michigan • Grand Rapids, Michigan • Gettysburg, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 30, 2026, 2:38 PM EDT
Terminated Phase 2 Interventional

Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection

NCT00087269
View directory record Official record
Conditions
Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
Interventions
erlotinib hydrochloride, therapeutic endoscopic surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 30, 2026, 2:38 PM EDT
Terminated Phase 1 Interventional

PF-07284892 in Participants With Advanced Solid Tumors

NCT04800822
View directory record Official record
Conditions
Solid Tumor
Interventions
PF-07284892, lorlatinib, binimetinib, cetuximab, encorafenib
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 2:38 PM EDT